The Role of Traditional and Modern Hormonal Therapy in Men with Biochemically Recurrent Prostate Cancer

摘要

Androgen deprivation (AD) achieved either surgically or , medically is the standard of care for men with metastatic prostate cancer. The role of AD in men with prostate-specific antigen (PSA)-only recurrence after definitive local therapies-such as radical prostatectomy and/or radiotherapy-is less well defined. A growing body of evidence points to the fact that AD is associated with both acute and chronic side effects, primarily related to a reduction in testosterone levels. Thus, in an attempt to preserve testosterone levels and improve quality of life while at the same time maintaining clinical efficacy, a variety of alternative approaches have been undertaken in this group of patients that generally will have prolonged exposure to AD. Peripheral androgen blockade (PAB) accomplished with antiandrogens alone or in combination with a 5alpha-reductase inhibitor has emerged as a potential option in this setting.